Watch for FDA response on TXM clinical hold and initiation of the human challenge trial; the PIPE removes near-term financing risk but adds dilution. Monitor insider buying pattern (recent $998K in purchases) for confidence signals.
Price Chart
Executive Summary
Traws Pharma reported Q1 2026 results with a net loss of $7.1M (-$0.53 EPS, beating the -$0.56 consensus) and zero revenue. The key event is the $60M PIPE financing (including $10M upfront) announced April 15, which extends cash runway into Q1 2027 and supports the upcoming TXM human challenge trial. The stock will likely respond to the funding and pipeline catalysts rather than the in-line earnings.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $7.1M, EPS -$0.53 (vs consensus -$0.56, a 5.4% beat)
- Zero revenue, down from $57K in Q1 2025
- Up to $60M PIPE financing closed April 15, with $10M upfront at $1.673/share; warrants could add ~$50M
- Cash and cash equivalents were $3.1M as of March 31, but post-PIPE runway expected into Q1 2027
- TXM (influenza) human challenge trial in UK expected to start in Q2 2026; US clinical hold on TXM remains
- Hantavirus program advancement with no approved treatments
Financial Impact
PIPE financing provides up to $60M in gross proceeds, extending runway into Q1 2027; net loss of $7.1M per quarter
Risk Factors
- Dilution from PIPE (5.98M shares issued plus potential warrant exercises)
- FDA clinical hold on TXM may delay US trials or require additional studies
- Low cash balance pre-PIPE ($3.1M) and no revenue; reliance on milestone warrant proceeds
- Pre-revenue clinical-stage biotech with binary pipeline events
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3295724 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | S-1 | $0.3500 | awaiting T+20 | — | $0.3700 (−5.71%) |
Oct 23, 2026 4d ago | 8-K | $0.3411 | awaiting T+20 | — | $0.3700 (−8.47%) |
Oct 20, 2026 7d ago | DEFA14A | $0.3760 | awaiting T+20 | — | $0.3700 (−1.60%) |
Oct 20, 2026 7d ago | DEF 14A | $0.3760 | awaiting T+20 | — | $0.3700 (+1.60%) |
Aug 14, 2026 10w ago | Press Release | $0.5400 $0.5200 | ▲ +3.70% | ▲ +2.18% | $0.3700 (+31.48%) |
Jul 10, 2026 15w ago | 8-K | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | 424B5 | $0.6849 $0.5400 | ▲ +21.16% | ▲ +24.34% | $0.3700 (+45.98%) |
Jul 10, 2026 15w ago | EFFECT | $0.7600 $0.5320 | ▲ +30.00% | ▲ +32.43% | $0.3700 (+51.32%) |
Jul 9, 2026 15w ago | 8-K | $0.7600 $0.5320 | ▼ −30.00% | ▼ −32.43% | $0.3700 (−51.32%) |
Jul 1, 2026 16w ago | S-3 | $0.7677 $0.4411 | ▼ −42.54% | ▼ −42.13% | $0.3700 (−51.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers